Duopharma’s new RM578mil contracts a positive

TA Research said it maintained its APPL sales contribution forecast for Duopharma at RM198mil for 2024.

PETALING JAYA: Duopharma Biotech Bhd’s shares gained 6.8% yesterday on news that the company has secured contracts worth RM578.1mil for the supply of pharmaceutical and/or non-pharmaceutical products.

Closing at RM1.26, the counter was up eight sen, off an intra-day high of RM1.29.

Uh-oh! Daily quota reached.


Experience an ad-free unlimited reading on both web and app.

Subscribe 
Follow us on our official WhatsApp channel for breaking news alerts and key updates!

Duopharma , pharmaceuticals , contracts , government , supply , healthcare , APPL , earnings , targetprice

   

Report it to us.

Next In Business News
Top HSBC shareholder Ping An will retain investment in bank, source says, amid sale talk
BWYS inks underwriting agreement with M&A Securities for ACE Market IPO
Anthony Loke: Proposed MAHB privatisation boosts efficiency
Asian FX ease, stocks struggle for direction on US rate uncertainty
Gold prices head for second weekly gain on Fed rate-cut optimism
Oil set for weekly gain on signs of improving demand
BNM's initiatives help cushion pressure on the ringgit
Stocks drift on uncertainty over timing of US rate cuts
China to cut mortgage interest rates, home down-payment ratio to boost demand
Itmax secures RM105.3mil contract from DBKL

Trending in Business

Others Also Read

Load more

Copyright © 1995- Star Media Group Berhad [197101000523 (10894-D)]

Best viewed on Chrome browsers.